Who founded AptamiR Therapeutics?

AptamiR Therapeutics was founded by Marc Thibonnier, M. Thibonnier in 2012.

How much funding has AptamiR Therapeutics raised?

AptamiR Therapeutics has disclosed $3M raised across 1 round.

Where is AptamiR Therapeutics headquartered?

AptamiR Therapeutics is headquartered in Austin, US.

AptamiR Therapeutics

Austin, US · Founded 2012 · Delaware corporation

Find your way into AptamiR Therapeutics

321 people in our graph share verified history with the AptamiR Therapeutics team — schools, employers, funds. One of them is your warm intro.

Shinobu Suzukiunlockedknows Marc Thibonnier · together at Bayer Pharmaceuticals (overlapped)

×9knows the team · via Bayer Pharmaceuticals

×2knows the team · via GlaxoSmithKline

AptamiR Therapeutics is a US biotechnology company in pre-clinical development of microRNA-based oligonucleotide therapeutics (antagomirs), including miR-22-3p drug candidates for cardiometabolic disorders such as obesity, diabetes and fatty liver disease (MAFLD/MASH) and candidates for epithelial ovarian cancer. Its approach modulates multiple target genes simultaneously to address complex metabolic diseases and cancer.

Biotech Healthtech Longevity

Founders & leadership

AptamiR Therapeutics was founded in 2012 by Marc Thibonnier and M. Thibonnier.

Marc Thibonnier Co-founderMarc Thibonnier is a physician-scientist with expertise in internal medicine, endocrinology, nephrology, and clinical pharmacology, holding over 150 peer-reviewed publications. He currently serves as Executive Officer and Director at AptamiR Therapeutics, a biotechnology company developing microRNA-based therapeutics for cardiometabolic and oncology indications.

M. Thibonnier

Philippe CamusExecutive

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2015

▶$3MraisedSep 2015 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Philippe CamusExecutive Officer, Director
Marc ThibonnierExecutive Officer, Director

Offering amount: $3M
Amount sold: $3M
Minimum investment: $3M
First sale: Sep 2015
Incorporated: Corporation, Delaware, 2012
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does AptamiR Therapeutics do?: AptamiR Therapeutics is a US biotechnology company in pre-clinical development of microRNA-based oligonucleotide therapeutics (antagomirs), including miR-22-3p drug candidates for cardiometabolic disorders such as obesity, diabetes and fatty liver disease (MAFLD/MASH) and candidates for epithelial ovarian cancer. Its approach modulates multiple target genes simultaneously to address complex metabolic diseases and cancer.
Who founded AptamiR Therapeutics?: AptamiR Therapeutics was founded by Marc Thibonnier, M. Thibonnier in 2012.
How much funding has AptamiR Therapeutics raised?: AptamiR Therapeutics has disclosed $3M raised across 1 round.
Where is AptamiR Therapeutics headquartered?: AptamiR Therapeutics is headquartered in Austin, US.